![]() | |
![]() | |
Clinical data | |
---|---|
Routes of administration | Oral, intranasal, rectal |
ATC code |
|
Legal status | |
Legal status | |
Pharmacokinetic data | |
Metabolism | Liver (CYP2D6) [2] |
Elimination half-life | 4–14 hours [2] [3] |
Excretion | Urine |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.026.959 |
Chemical and physical data | |
Formula | C10H13ClN2 |
Molar mass | 196.68 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
meta-Chlorophenylpiperazine (mCPP) is a psychoactive drug of the phenylpiperazine class. It was initially developed in the late-1970s and used in scientific research before being sold as a designer drug in the mid-2000s. [4] [5] It has been detected in pills touted as legal alternatives to illicit stimulants in New Zealand and pills sold as "ecstasy" in Europe and the United States. [6] [7]
Despite its advertisement as a recreational substance, mCPP is actually generally considered to be an unpleasant experience and is not desired by drug users. [6] It lacks any reinforcing effects, but has "psychostimulant, anxiety-provoking, and hallucinogenic effects." [8] [9] [10] [11] It is also known to produce dysphoric, depressive, and anxiogenic effects in rodents and humans, [12] [13] and can induce panic attacks in individuals susceptible to them. [14] [15] [16] [17] It also worsens obsessive–compulsive symptoms in people with the disorder. [18] [19] [20]
mCPP is known to induce headaches in humans and has been used for testing potential antimigraine medications. [21] [22] [23] It has potent anorectic effects and has encouraged the development of selective 5-HT2C receptor agonists for the treatment of obesity as well. [24] [25] [26] [27]
Site | Ki (nM) | Species | Refs |
---|---|---|---|
SERT | 202–432 | Human | [29] |
NET | 1,940–4,360 | Human | [29] |
DAT | ND | ND | ND |
5-HT1A | 44–400 | Human | [28] [30] |
5-HT1B | 89–501 | Human | [28] [31] |
5-HT1D | 210–1,300 | Human | [30] [32] |
5-HT1E | ND | ND | ND |
5-HT1F | ND | ND | ND |
5-HT2A | 32–398 | Human | [28] [11] [30] [33] |
5-HT2B | 3.2–63 | Human | [28] [34] [35] |
5-HT2C | 3.4–251 | Human | [28] [11] [33] [36] |
5-HT3 | 427 | Human | [28] |
5-HT4 | ND | ND | ND |
5-HT5A | 1,354 | Human | [28] |
5-HT6 | 1,748 | Human | [28] |
5-HT7 | 163 | Human | [28] |
α1 | 97–2,900 | Human | [29] [30] |
α1A | 1,386 | Human | [28] |
α1B | 915 | Human | [28] |
α1D | ND | ND | ND |
α2 | 112–570 | Human | [29] [30] |
α2A | 145 | Human | [28] |
α2B | 106 | Human | [28] |
α2C | 124 | Human | [28] |
β | 2,500 | Human | [30] |
β1 | 2,359 | Human | [28] |
β2 | 3,474 | Human | [28] |
D1 | 7,000 | Human | [30] |
D2 | >10,000 | Human | [30] |
D3 | >10,000 | Rat | [28] |
D4 | ND | ND | ND |
D5 | >10,000 | Human | [28] |
H1 | 326 | Human | [28] |
mAChRs | >10,000 | Human | [30] |
nAChRs | >10,000 | Human | [28] |
σ1 | ND | ND | ND |
σ2 | 8,350 | Rat | [28] |
I1 | 759 | Rat | [28] |
VDCC | 6,043 | Rat | [28] |
Values are Ki (nM). The smaller the value, the more strongly the drug binds to the site. |
mCPP possesses significant affinity for the 5-HT1A, 5-HT1B, 5-HT1D, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT3, and 5-HT7 receptors, as well as the SERT. [28] It also has some affinity for α1-adrenergic, α2-adrenergic, H1, I1, and NET. [28] [37] It behaves as an agonist at most serotonin receptors. [38] [39] mCPP has been shown to act not only as a serotonin reuptake inhibitor but as a serotonin releasing agent as well. [40]
mCPP's strongest actions are at the 5-HT2B and 5-HT2C receptors and its discriminative cue is mediated primarily by 5-HT2C. [28] [41] [42] Its negative effects such as anxiety, headaches, and appetite loss are likely mediated by its actions on the 5-HT2C receptor. [13] [24] [43] Other effects of mCPP include nausea, hypoactivity, and penile erection, the latter two the result of increased 5-HT2C activity and the former likely via 5-HT3 stimulation. [44] [45] [46]
In comparison studies, mCPP has approximately 10-fold selectivity for the human 5-HT2C receptor over the human 5-HT2A and 5-HT2B receptors (Ki = 3.4 nM vs. 32.1 and 28.8 nM). [11] It acts as a partial agonist of the human 5-HT2A [47] and 5-HT2C [48] receptors but as an antagonist of the human 5-HT2B receptors. [49]
mCPP is metabolized via the CYP2D6 isoenzyme by hydroxylation to para-hydroxy-mCPP (p-OH-mCPP) and this plays a major role in its metabolism. [2] [50] [51] The elimination half-life of mCPP is 4 to 14 hours. [2]
mCPP is a metabolite of a variety of other piperazine drugs including trazodone, nefazodone, etoperidone, enpiprazole, mepiprazole, cloperidone, peraclopone, and BRL-15,572. [51] [ additional citation(s) needed ] It is formed by dealkylation via CYP3A4. [51] Caution should be exercised in concomitant administration of CYP2D6 inhibitors such as bupropion, fluoxetine, paroxetine, and thioridazine with drugs that produce mCPP as a metabolite as these drugs are known to increase concentrations of the parent molecule (e.g., trazodone) and of mCPP. [50] [2]
Analogues of mCPP include:
Some additional analogues include quipazine, ORG-12962, and 3C-PEP.
mCPP is illegal in Belgium. [52]
mCPP is not a controlled drug in Canada.
As of October 2015 mCPP is a controlled substance in China. [54]
mCPP is legal in the Czech Republic. [55]
mCPP is illegal in Denmark. [56] [ unreliable source? ]
mCPP is illegal in Finland.
mCPP is illegal in Germany.
mCPP is illegal in Hungary since 2012.
mCPP is illegal in Japan since 2006.
mCPP is legal in the Netherlands. [57]
Based on the recommendation of the EACD, the New Zealand government has passed legislation which placed BZP, along with the other piperazine derivatives TFMPP, mCPP, pFPP, MeOPP and MBZP, into Class C of the New Zealand Misuse of Drugs Act 1975. A ban was intended to come into effect in New Zealand on December 18, 2007, but the law change did not go through until the following year, and the sale of BZP and the other listed piperazines became illegal in New Zealand as of 1 April 2008. An amnesty for possession and usage of these drugs remained until October 2008, at which point they became completely illegal. [58] However, it is important to note that mCPP is legally used for scientific research.
mCPP is illegal in Norway.
mCPP is illegal in Russia.
mCPP is illegal in Sweden.
mCPP is illegal in Poland.
mCPP is not scheduled at the federal level in the United States, [59] but it is possible that it could be considered a controlled substance analog of BZP, in which case purchase, sale, or possession could be prosecuted under the Federal Analog Act.
However, "chlorophenylpiperazine" is a Schedule I controlled substance in the state of Florida making it illegal to buy, sell, or possess in this state. [60]
5-HT receptors, 5-hydroxytryptamine receptors, or serotonin receptors, are a group of G protein-coupled receptor and ligand-gated ion channels found in the central and peripheral nervous systems. They mediate both excitatory and inhibitory neurotransmission. The serotonin receptors are activated by the neurotransmitter serotonin, which acts as their natural ligand.
Benzylpiperazine (BZP) is a substance often used as a recreational drug and is known to have euphoriant and stimulant properties. Several studies conducted between 2000 and 2011 found that the effects of BZP are similar to amphetamine, although BZP's dosage is roughly 10 times higher by weight.
3-Trifluoromethylphenylpiperazine (TFMPP) is a recreational drug of the phenylpiperazine chemical class and is a substituted piperazine. Usually in combination with benzylpiperazine (BZP) and other analogues, it is sold as an alternative to the illicit drug MDMA ("Ecstasy").
Trazodone, sold under many brand names, is an antidepressant medication. It is used to treat major depressive disorder, anxiety disorders, and insomnia. The medication is taken orally.
Lisuride, sold under the brand name Dopergin among others, is a monoaminergic medication of the ergoline class which is used in the treatment of Parkinson's disease, migraine, and high prolactin levels. It is taken by mouth.
The 5-HT2A receptor is a subtype of the 5-HT2 receptor that belongs to the serotonin receptor family and is a G protein-coupled receptor (GPCR). The 5-HT2A receptor is a cell surface receptor, but has several intracellular locations.
A serotonin receptor agonist is an agonist of one or more serotonin receptors. They activate serotonin receptors in a manner similar to that of serotonin, a neurotransmitter and hormone and the endogenous ligand of the serotonin receptors.
para-Fluorophenylpiperazine is a piperazine derivative with mildly psychedelic and euphoriant effects. It has been sold as an ingredient in legal recreational drugs known as "Party pills", initially in New Zealand and subsequently in other countries around the world.
5-Hydroxytryptamine receptor 2B (5-HT2B) also known as serotonin receptor 2B is a protein that in humans is encoded by the HTR2B gene. 5-HT2B is a member of the 5-HT2 receptor family that binds the neurotransmitter serotonin (5-hydroxytryptamine, 5-HT). Like all 5-HT2 receptors, the 5-HT2B receptor is Gq/G11-protein coupled, leading to downstream activation of phospholipase C.
YM-348 is an indazole derivative drug which acts as a potent and selective 5-HT2C receptor agonist, with an EC50 of 1nM and 15x selectivity over 5-HT2A, although it only has moderate selectivity of 3x over the closely related 5-HT2B receptor. It has thermogenic and anorectic effects in animal studies, making it potentially useful for the treatment of obesity.
BW-723C86 is a tryptamine derivative drug which acts as a 5-HT2B receptor agonist. It has anxiolytic effects in animal studies, and is also used for investigating the function of the 5-HT2B receptor in a range of other tissues.
Ro60-0175 is a drug developed by Hoffmann–La Roche, which has applications in scientific research. It acts as a potent and selective agonist for both the 5-HT2B and 5-HT2C serotonin receptor subtypes, with good selectivity over the closely related 5-HT2A subtype, and little or no affinity at other receptors.
SDZ SER-082 is a drug which acts as a mixed antagonist for the 5-HT2B and 5-HT2C serotonin receptors, with good selectivity over other serotonin receptor subtypes and slight preference for 5-HT2C over 5-HT2B. It has been used in animal studies into the behavioural effects of the different 5-HT2 subtypes, and how they influence the effects of other drugs such as cocaine.
Serotonin antagonist and reuptake inhibitors (SARIs) are a class of drugs used mainly as antidepressants, but also as anxiolytics and hypnotics. They act by antagonizing serotonin receptors such as 5-HT2A and inhibiting the reuptake of serotonin, norepinephrine, and/or dopamine. Additionally, most also antagonize α1-adrenergic receptors. The majority of the currently marketed SARIs belong to the phenylpiperazine class of compounds.
1-(1-Naphthyl)piperazine (1-NP) is a drug which is a phenylpiperazine derivative. It acts as a non-selective, mixed serotonergic agent, exerting partial agonism at the 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E, and 5-HT1F receptors, while antagonizing the 5-HT2A, 5-HT2B, and 5-HT2C receptors. It has also been shown to possess high affinity for the 5-HT3, 5-HT5A, 5-HT6, and 5-HT7 receptors, and may bind to 5-HT4 and the SERT as well. In animals it produces effects including hyperphagia, hyperactivity, and anxiolysis, of which are all likely mediated predominantly or fully by blockade of the 5-HT2C receptor.
SB-206553 is a drug which acts as a mixed antagonist for the 5-HT2B and 5-HT2C serotonin receptors. It has anxiolytic properties in animal studies and interacts with a range of other drugs. It has also been shown to act as a positive allosteric modulator of α7 nicotinic acetylcholine receptors. Modified derivatives of SB-206553 have been used to probe the structure of the 5-HT2B receptor.
MK-212 is a serotonin agonist. It promotes the secretion of serum prolactin and cortisol in humans.
5-HT2C receptor agonists are a class of drugs that activate 5-HT2C receptors. They have been investigated for the treatment of a number of conditions including obesity, psychiatric disorders, sexual dysfunction and urinary incontinence.
25CN-NBOH is a compound indirectly derived from the phenethylamine series of hallucinogens, which was discovered in 2014 at the University of Copenhagen. This compound is notable as one of the most selective agonist ligands for the 5-HT2A receptor yet discovered, with a pKi of 8.88 at the human 5-HT2A receptor and with 100x selectivity for 5-HT2A over 5-HT2C, and 46x selectivity for 5-HT2A over 5-HT2B. A tritiated version of 25CN-NBOH has also been accessed and used for more detailed investigations of the binding to 5-HT2 receptors and autoradiography.
CPD-1 (LS-193743) is a drug with a benzofuranyl piperazine structure, which acts as a potent and selective agonist for the 5-HT2 receptor family, with highest affinity and full agonist efficacy at the 5-HT2C subtype, and lower affinity and partial agonist action at the 5-HT2A and 5-HT2B subtypes.